IPP Bureau
Merck completes tender offer to acquire Imago BioSciences
By IPP Bureau - January 12, 2023
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
Moderna to acquire Oriciro Genomics
By IPP Bureau - January 11, 2023
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
By IPP Bureau - January 11, 2023
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Merck named one of America’s Most JUST Companies by JUST Capital and CNBC
By IPP Bureau - January 11, 2023
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain
By IPP Bureau - January 10, 2023
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
Sirio Pharma successfully completes acquisition of Best Formulations
By IPP Bureau - January 10, 2023
With more than 35 years of experience, Best Formulations is the largest manufacturer of plant-based softgels in the United States, with newly expanded capabilities for nutritional gummies and personal care
NHA introduces new system to measure hospitals performance empaneled under AB PM-JAY Scheme
By IPP Bureau - January 10, 2023
The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services
Vidita Vaidya awarded Infosys Prize 2022 in Life Sciences
By IPP Bureau - January 10, 2023
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
Moderna announces advances across mRNA pipeline
By IPP Bureau - January 10, 2023
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
GenNext Technologies appoints Dr. John Grant to its Board of Directors
By IPP Bureau - January 10, 2023
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
Zydus receives final approval from the USFDA for Febuxostat Tablets
By IPP Bureau - January 10, 2023
Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).
Lupin receives approval from USFDA for Prasugrel Tablets, USP
By IPP Bureau - January 10, 2023
ProBioGen collaborates with Boehringer Ingelheim on DirectedLuck transposase technology
By IPP Bureau - January 10, 2023
The new project further expands the partner's long-term collaboration on new technologies for R&D
Suburban Diagnostics unveils Reference Laboratory in Mumbai
By IPP Bureau - January 09, 2023
The lab is also the first private lab in West India to have built its Mycobacteriology, Mycology, and Molecular Biology departments within a separate Bio Safety Level - 3 (BSL3) bio-containment lab
Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar
By IPP Bureau - January 09, 2023
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
